Two Decades of Pioneering Innovation in CML and Beyond
A Breakthrough for CML and Cancer TreatmentIn May 2001 – exactly 20 years ago – Novartis received approval from the US Food and Drug Administration (FDA) for the first targeted therapy for cancer, known as a tyrosine kinase inhibitor (TKI). This was a …